Table 2 POAG incidence in ESRD patients, KTRs, and healthy controls.

From: Nationwide Glaucoma incidence in end stage renal disease patients and kidney transplant recipients

Group

N

POAG Incidence

Duration (person- years)

Incidence rate (/1,000 person-years)

Unadjusted

Model 1

Model 2

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

Healthy Control

10,955

77

64,358.35

1.20

1 (Ref.)

 

1 (Ref.)

 

1 (Ref.)

 

ESRD

10,955

180

53,507.48

3.36

2.83 (2.17–3.70)

 < 0.0001

2.95 (2.26–3.85)

 < 0.0001

1.43 (0.97–2.12)

0.07

KTR

10,955

200

62,107.74

3.22

2.69 (2.07–3.50)

 < 0.0001

2.72 (2.09–3.54)

 < 0.0001

1.41 (0.96–2.07)

0.08

ESRD

10,955

180

53,507.48

3.36

1 (Ref.)

 

1 (Ref.)

 

1 (Reference)

 

KTR

10,955

200

62,107.74

3.22

0.95 (0.78–1.17)

0.65

0.928 (0.76–1.14)

0.47

1.02 (0.83–1.26)

0.84

  1. Model 1: Cox proportional hazard (PH) regression model adjusted for age and sex.
  2. Model 2: Cox proportional hazard (PH) regression model adjusted for age, sex, diabetes mellitus, hypertension, dyslipidemia, income, and Charlson comorbidity index.
  3. POAG primary open-angle glaucoma, HR hazard ratio, CI confidence interval, ESRD end stage renal disease, KTR kidney transplantation recipients.
Back to article page